Main > ONCOLOGY (**) > Lung>NSCLC>MET>PD-L1+>> *** > Treatment > USA. M. PembrolizuMAb
USA. M. PembrolizuMAb's subsections
(*) EU Approval Date: 2017. 01.31.
(*) JP Approval Date: 2016. 12.19.
(*) USA Approval Date: 2016. 10.24
>IDEM. To Co: CH. R. AtezolizuMAb
>IDEM. To Co: CH. R. AtezolizuMAb
Companion Diagnostics>
Company
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 4
Patent>UpDate: 2018. 10.23.
PD-L1: Programmed Death Ligand 1
TradeMark
TradeMark Web-Site
USA. M. PembrolizuMAb's products
This section has no products